Welcome to your Weekly Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Dilon Technologies Gets FDA Approval for MarginProbe 2 Launch
Dilon Technologies, a leading provider of medical devices, has gained FDA approval for its MarginProbe 2 system and is announcing its launch in the U.S. This is the next-generation device for real-time intraoperative margin assessment in breast cancer surgery. MarginProbe 2 is designed to help surgeons achieve greater precision during breast-conserving surgeries, reducing the need for additional procedures and improving patient outcomes.
Link Cell Therapies Launches to Advance CAR-T Cancer Treatments
Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. , with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors.
Infinitus Launches Next-Generation Clinical AI Agents
Infinitus Systems Inc., a leader in agent-powered healthcare communications that supports over 100 million minutes of patient conversations, has introduced a new generation of clinical AI agents designed for patient-facing interactions. These advanced agents are built to help healthcare organizations strengthen their care delivery by supporting patient education, care coordination, health risk evaluations, and other clinical communication needs. The launch reflects Infinitus’ focus on creating secure, empathetic, and intelligent tools that work alongside human care teams rather than replacing them.
Hercules Pharmaceuticals Appoints Ali Ahmed as Chief Commercial Officer
Hercules Pharmaceuticals announced the appointment of Ali Ahmed as Executive Vice President, Chief Commercial Officer. Ahmed will lead commercial strategy, enterprise growth, and strategic partnerships as Hercules scales its national platform and expands its role as a strategic partner within the U.S. pharmaceutical distribution ecosystem.
Pulse Biosciences Gets FDA IDE for nPulse AFib Ablation Study
Pulse Biosciences, Inc. , a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation energy, announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company’s Investigational Device Exemption (IDE), allowing Pulse Biosciences to proceed with the initiation of its nPulse Cardiac Catheter Ablation System Study for the treatment of paroxysmal atrial fibrillation.
PROSTOX Ultra Test Cuts Costs and Boosts Quality of Life in Prostate Cancer
MiraDx, a molecular diagnostics company specializing in germline genetic testing to personalize cancer treatment, announced that a new study published in the Journal of Health Economics and Outcomes Research shows the PROSTOX ultra test provides meaningful long-term economic and quality-of-life benefits for men with localized prostate cancer undergoing stereotactic body radiation therapy.
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion
BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The agreement has been unanimously approved by the Boards of Directors of both companies and Amicus’ Board of Directors unanimously recommended that Amicus’ stockholders vote to adopt the agreement. The transaction is expected to close in the second quarter of 2026, subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions.
Linus Health AI Validated as Early Digital Biomarker for Alzheimer’s Pathology
AI can detect biological signs of Alzheimer’s disease years before symptoms are noted by the patient or their loved ones using only a 3-minute digital assessment delivered in a physician’s office. New research from Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized intervention, shows that this same short test can also signal cognitive impairment and flag patients who should undergo further testing with blood-based, PET, or CSF biomarkers to enable earliest disease detection when action has the greatest potential to change disease trajectory and prevent, minimize, or slow down disability.
OPUM Technologies Boosts AI Biomechanics Platform, Taps Regiment Bank
OPUM Technologies, a medical technology company focused on transforming knee health, performance, and recovery, announced significant growth of its Digital Knee platform, an AI-driven wearable and analytics system delivering continuous, clinical-grade biomechanical insights. The company also named Regiment Securities LLC as its exclusive investment bank to guide strategic planning and capital initiatives. The Digital Knee platform integrates patented sensors, motion analytics, and artificial intelligence to track real-world knee biomechanics continuously, offering data far beyond traditional assessments or subjective observation.
Lumicell Partners with Learn Look Locate to Educate Breast Cancer Patients
Lumicell, Inc., a pioneer in fluorescence-guided imaging technologies for cancer detection, announced a new collaboration with Learn Look Locate, a global platform focused on breast cancer education. This partnership aims to provide patients with clear, accessible information about their diagnosis and treatment options while highlighting the role of advanced technologies in breast-conserving surgery. Through the collaboration, Lumicell and Learn Look Locate will develop educational resources that help patients understand surgical procedures, emerging innovations, and how tools like LumiSystem assist surgeons in identifying residual cancer during lumpectomy.
To share your insights, please write to us at sudipto@intentamplify.com
